US, Canada, and EU – Who wins the Drug Approval Race?

Both pharmaceutical industry and regulatory professionals acknowledge the importance of balancing timely access to new medicines with the need for thorough review of drug safety and efficacy data. preo ivermectina 6mg 4 comprimidos drogasil   A new study, funded by...

Nonclinical Toxicology: FDA Guidance Agenda for 2012

The Federal Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has issued a list of planned draft and final guidance documents for release in 2012. لعبة الكازينو   There are about 50 such guidances planned.  Below are a few select highlights...

Nonclinical Toxicology Sector Predictions for 2012

Growth in demand for nonclinical toxicology services will be weak for the foreseeable future analysts said after the Society of Toxicology (SOT) annual meeting in San Francisco this past week. كيف تربح في الروليت   “Most agree that the industry is not merely going...

Dried Blood Spot Analysis: Preclinical Considerations

A previous entry detailed Dried Blood Spot Analysis: Preclinical Pros and Cons.  Additional preclinical considerations include the ambiguity of acceptance by global regulatory agencies, none of which have issued definitive rulings on how they’ll handle New Drug...